New Issue: Orbital Catastrophe Ahead? Read Now

Visions for Psychedelics

Join Our Community of Science Lovers!

A single dose of psilocybin, the active ingredient in the infamous psychedelic mushrooms indigenous to Mexico, triggered long-lasting mystical experiences in several dozen middle-aged volunteers enrolled in an unusual study at Johns Hopkins University.

Roland Griffiths and his colleagues brought 36 people into the laboratory for an eight-hour session during which they experienced their first psychedelic high. Two thirds of them said that the trip was among the most profound spiritual events in their life, Griffiths reports. A third rated it as their number-one awakening, and their family and co-workers said they seemed happier in the months after the experiment, according to a follow-up study just concluded.

Griffiths says he embarked on the controversial experiment because psychedelics constitute “a whole class of drugs we know very little about.” Research came to a halt after investigators such as Harvard University’s Timothy Leary in the heady 1960s swallowed their own research pills in the name of science. Griffiths says the findings suggest these drugs, or safer versions of them, could be used to treat addictions, because many recovery programs are based on models of spirituality. The drugs could also help overcome depression.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Johns Hopkins recruited people with no history of mental illness or psychedelic drug use. Each volunteer received eight hours of preparation. Their trip took place in a living room setting with two monitors present. Half received the real drug, and the others were given an amphetamine or a placebo. According to Griffiths, the subjects who received psilocybin said they “had a sense of pure awareness. They described feeling infinite love, tenderness and peace. Everything was experienced in the present; the past and future had no meaning.” Nevertheless, a third of these volunteers felt significant fears afterward, and some experienced paranoia. “These drugs should not be used recreationally,” Griffiths notes.

SA Mind Vol 17 Issue 5This article was published with the title “Visions for Psychedelics” in SA Mind Vol. 17 No. 5 (), p. 7
doi:10.1038/scientificamericanmind1006-7b

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe